The EU pharmaceutical industry has warned that the bloc is lagging behind when it comes to innovation and losing its position in the global market.
For instance, the US industry’s pharma research grew at twice the rate of Europe’s between 2017 and 2019.
The disparities between the US and Europe are also evident from the perspective of patients who are concerned about the accessibility of new drugs.
Currently, it takes on average 150 days longer to get an innovative medicine approved in Europe than in the US – time that could be crucial for some patients…
